BoGuo et al. report that the treatment of CD138 CAR-T is safe, feasible, and tolerable and has potential anti-tumor activity in vivo, warranting further research into MM treatment with CD138 CAR-T [56]. Here, SDC1 is linked to Miyoshi myopathy.